This Article Full Text Full Text (PDF) All Versions of this Article: 112/9/1284    most recent CIRCULATIONAHA.104.530329v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ishii, H. Articles by Matsubara, T. Search for Related Content PubMed PubMed Citation Articles by Ishii, H. Articles by Matsubara, T. Related Collections Cardiovascular Pharmacology Catheter-based coronary and valvular interventions: other Acute myocardial infarction Related Article

(Circulation. 2005;112:1284-1288.)
© 2005 American Heart Association, Inc.

Coronary Heart Disease

Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment–Elevation Myocardial Infarction

Hideki Ishii, MD; Satoshi Ichimiya, MD, PhD; Masaaki Kanashiro, MD, PhD; Tetsuya Amano, MD, PhD; Kenji Imai, MD, PhD; Toyoaki Murohara, MD, PhD; Tatsuaki Matsubara, MD, PhD

From the Department of Cardiology, Nagoya University Graduate of School of Medicine (H.I., T.A., K.J., T. Murohara); the Department of Cardiology, Yokkaichi Municipal Hospital, Yokkaichi, Mie (H.I., S.I., M.K.); and the Department of Internal Medicine, School of Dentistry, Aichi-Gakuin University (T. Matsubara), Nagoya, Japan.

Correspondence to Dr Hideki Ishii, Department of Cardiology, Nagoya University Graduate of School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. E-mail hkishii{at}med.nagoya-u.ac.jp

Received December 20, 2004; revision received May 5, 2005; accepted May 31, 2005.

Background— Intravenous nicorandil, a hybrid compound of ATP-sensitive potassium channel opener and nitric oxide donor, has been reported to ameliorate early functional and clinical problems in patients with acute myocardial infarction. However, its effects on the late phase remain unclear.

Methods and Results— This follow-up study to 5 years of a randomized, double-blinded trial was conducted among 368 patients with first ST-segment–elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). They were randomly assigned to receive 12 mg of nicorandil or a placebo intravenously just before reperfusion. We analyzed incidence of cardiovascular death or rehospitalization for congestive heart failure after PCI as well as various aspects of epicardial flow and microvascular function. Mean follow-up was 2.4 years (SD, 1.4). A total of 12 (6.5%) patients receiving nicorandil and 30 (16.4%) receiving placebo had cardiovascular death or hospital admission for congestive heart failure (hazard ratio, 0.39; 95% CI, 0.20 to 0.76; P=0.0058). Postprocedural TIMI 3 flow was obtained in 89.7% of the nicorandil group and in 81.4% of the placebo (hazard ratio, 1.99; 95% CI, 1.09 to 3.65; P=0.025). Corrected TIMI frame count was furthermore lower in the nicorandil group (21.0±9.1 versus 25.1±14.1; P=0.0009). ST-segment resolution >50% was observed in 79.5% and 61.2% of the nicorandil and placebo groups, respectively (hazard ratio, 2.45; 95% CI, 1.54 to 3.90; P=0.0002).

Conclusions— The addition of intravenous nicorandil to PCI leads to beneficial clinical outcomes and prevents cardiovascular events of long duration and death in patients with ST-segment–elevation myocardial infarction.

Key Words: myocardial infarction • reperfusion • microcirculation • pharmacology

Related Article:

Issue Highlights
Circulation 2005 112: 1241. [Full Text]

This article has been cited by other articles:

				R. Jaffe, T. Charron, G. Puley, A. Dick, and B. H. Strauss Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous Coronary Intervention Circulation, June 17, 2008; 117(24): 3152 - 3156. [Full Text] [PDF]

				P. A. Grayburn and J. W. Choi Advances in the assessment of no-reflow after successful primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: now that we can diagnose it, what do we do about it? J. Am. Coll. Cardiol., February 5, 2008; 51(5): 566 - 568. [Full Text] [PDF]

				R. M. Mentzer Jr, M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2008; 3(2008): 443 - 464. [Full Text]

				S. Kasama, T. Toyama, H. Sumino, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Long-Term Nicorandil Therapy Improves Cardiac Sympathetic Nerve Activity After Reperfusion Therapy in Patients with First Acute Myocardial Infarction J. Nucl. Med., October 1, 2007; 48(10): 1676 - 1682. [Abstract] [Full Text] [PDF]

				D. M. Yellon and D. J. Hausenloy Myocardial Reperfusion Injury N. Engl. J. Med., September 13, 2007; 357(11): 1121 - 1135. [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1689 - 1706. [Full Text] [PDF]

				H. Ishii, S. Ichimiya, M. Kanashiro, T. Amano, T. Matsubara, and T. Murohara Effects of Intravenous Nicorandil Before Reperfusion for Acute Myocardial Infarction in Patients With Stress Hyperglycemia Diabetes Care, February 1, 2006; 29(2): 202 - 206. [Abstract] [Full Text] [PDF]